Browsing by Author "Gallego, J."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
    (2019) Carmona-Bayonas, A.; Jimenez-Fonseca, P.; Garrido S., Marcelo; Custodio, A.; Hernandez, R.; Lacalle, A.; Cano, J.M.; Aguado, G.; De Castro, E.M.; Mancenido, F.A.; Macias, I.; Visa, L.; Richard, M.M.; Mangas, M.; Canovas, M.S.; Longo, F.; Rey, L.I.; Lago, N.M.; Carnicero, A.M.; Sanchez, A.; Azkarate, A.; Limon, M.L.; Perez, C.H.; Ramchandani, A.; Pimentel, P.; Cerda, P.; Serrano, R.; Gil-Negrete, A.; Marin, M.; Hurtado, A.; Bayona, R.S.; Gallego, J.
  • Thumbnail Image
    Item
    Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
    (SPRINGER INTERNATIONAL PUBLISHING AG, 2020) Viudez, A.; Carmona Bayonas, A.; Gallego, J.; Lacalle, A.; Hernandez, R.; Cano, J. M.; Macias, I; Custodio, A.; Martinez de Castro, E.; Sanchez, A.; Iglesia, L.; Reguera, P.; Visa, L.; Azkarate, A.; Sanchez Canovas, M.; Mangas, M.; Limon, M. L.; Martinez Torron, A.; Asensio, E.; Ramchandani, A.; Martin Carnicero, A.; Hurtado, A.; Cerda, P.; Garrido, M.; Sanchez Bayonas, R.; Serrano, R.; Jimenez Fonseca, P.; AGAMENON Study Grp
    Background The optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed different strategies including limited treatment, maintenance of some drugs, or treatment until progression. Method The sample comprises patients from the AGAMENON multicenter registry without progression after second evaluation of response. The objective was to explore the optimal duration of first-line chemotherapy. A frailty multi-state model was conducted. Results 415 patients were divided into three strata: discontinuation of platinum and maintenance with fluoropyrimidine until progression (30%, n = 123), complete treatment withdrawal prior to progression (52%, n = 216), and full treatment until progression (18%, n = 76). The hazard of tumor progression decreased by 19% per month with the full treatment regimen. However, we found no evidence that fluoropyrimidine maintenance (hazard ratio [HR] 1.07, confidence interval [CI] 95%, 0.69-1.65) worsened progression-free survival (PFS) with respect to treatment until progression. Predictive factors for PFS were ECOG performance status, >= 3 metastatic sites, prior tumor response, and bone metastases. Toxicity grade 3/4 was more common in those who continued the full treatment until progression vs fluoropyrimidine maintenance (16% vs 6%). Conclusion The longer duration of the full initial regimen exerted a protective effect on the patients of this registry. Platinum discontinuation followed by fluoropyrimidine maintenance yields comparable efficacy to treatment up to PD, with a lower rate of serious adverse events.